Navigation Links
Delcath to Present at Upcoming Investor Conferences
Date:3/2/2011

NEW YORK, March 2, 2011 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that executive management will present an overview of the Company's business strategy and recent corporate developments at the following investor conferences:

  • The Cowen and Company Healthcare Conference in Boston.  Mr. Eamonn Hobbs, Chief Executive Officer, and Mr. David McDonald, Chief Financial Officer, are scheduled to present an overview of the Company on Tuesday, March 8, 2011 at 10:15 a.m. ET.
  • ROTH Capital Annual OC Growth Stock Conference in Laguna Niguel, California.  Mr. Hobbs is scheduled to present an overview of the Company on Monday, March 14, 2011 at 1:30 p.m. PT.

  • Attendance at each of these conferences is by invitation only. Delcath will offer live and audio webcasts of its presentation, which may be accessed on the Investor Relations section of the Company's website at www.delcath.com.  An archived replay of the presentations will be available for 90 days, also at www.delcath.com.

    About Delcath SystemsDelcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com.

    The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are made.Contact Information:Investor Contact:

    Media Contact:Gregory Gin/Doug Sherk

    Janine McCargoEVC Group

    EVC Group646-445-4801/415-896-6818

    646-688-0425
    '/>"/>

    SOURCE Delcath Systems, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Delcath Systems Receives Refusal to File Letter From FDA
    2. Delcath Achieves ISO 13485 Certification
    3. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
    4. Delcath Systems Announces Third Quarter Progress Report Conference Call
    5. Delcath Strengthens Research and Development Team with Key Appointments
    6. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
    7. Delcath to Present at the William Blair Emerging Growth Stock Conference
    8. Delcath to Present at the JMP Securities Healthcare Conference
    9. Delcath Systems Announces Completion of Common Stock Offering
    10. Delcath to Present at the 30th Annual Canaccord Global Growth Conference
    11. Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
    (Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
    (Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
    (Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
    (Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
    (Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
    (Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
    Breaking Medicine News(10 mins):